🏛️ Verified NIH Record • Updated 2026-05-08
A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome (NCT07432490)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Oregon Health and Science University
🩺 Plain-English Summary (8th-Grade Level)
This is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of L-fucose supplementation in subjects with GLUT1 deficiency syndrome (GLUT1DS).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (12 items).
Location: Oregon Health and Science University — Portland, Oregon
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Inability to swallow liquids
- Change in neurological medications (either medication itself or medication dosages) in the past 90 days
- Use of fucose- or mannose-containing supplements within one year of enrollment
- Presence of hepatic, renal, hematological, or concomitant metabolic disorders, as assessed by the presence of a previous diagnosis of such disorders (for instance, chronic kidney disease, liver cirrhosis, diabetes mellitus) or by the following laboratory values, which will be considered if obtained clinically up to 90 days before enrollment (if this is not available, laboratory tests will be obtained prior to first study visit):
- Any degree of hepatic impairment based on the Child-Pugh classification
- eGFR (as measured by serum creatinine or cystatin C) \< 60 mg/min/1.73m2
- Hemoglobin A1c \> 6.5%
- Hemoglobin level below the lower limit of normal (LLN) for sex and age
- Platelet counts below the LLN for sex and age
- Subjects who are pregnant, breastfeeding, or planning to become pregnant within one year of enrollment
- Enrollment in an investigational new drug trial for G1DS within one year of enrollment
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Oregon Health and Science University — Portland, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.